Trials / Completed
CompletedNCT04440956
An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours
Positron Emission Tomography (PET) Imaging of Patients With Low & Intermediate Grade Neuroendocrine Tumors Using 64Cu-SARTATE: A Single Centre, Open-Label, Non-Randomized, Phase-0 Microdosing Investigation
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Clarity Pharmaceuticals Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to examine the safety and potential effectiveness of a drug molecule called 64Cu-SARTATE as a potential new way to detect neuroendocrine cancers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 64Cu-SARTATE | 200MBq of 64Cu-MeCOSar-Octreotate ("64Cu-SARTATE") given as a single bolus intravenous injection and peptide mass will not exceed 10micrograms. |
Timeline
- Start date
- 2015-05-21
- Primary completion
- 2016-02-25
- Completion
- 2016-02-25
- First posted
- 2020-06-22
- Last updated
- 2020-06-22
Source: ClinicalTrials.gov record NCT04440956. Inclusion in this directory is not an endorsement.